Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Inhibikase Therapeutics, Inc. (IKT) vs Upstream Bio, Inc. (UPB)

Inhibikase Therapeutics, Inc. and Upstream Bio, Inc. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and Upstream Bio, Inc. are of similar size ($293.0M and $283.2M). Inhibikase Therapeutics, Inc. grew revenue faster over the last twelve months: 110.9% against 16.0%. Inhibikase Therapeutics, Inc. has the higher net margin (0.00% vs −4,955.7%) and the higher return on invested capital (0.00% vs −1,100.9%). Across the 15 metrics below, Inhibikase Therapeutics, Inc. leads on 8 and Upstream Bio, Inc. on 7.

Valuation

Metric IKT UPB Biotechnology median
P/E n/m n/m 7.88
P/S 1,380.49 92.62 11.47
P/B 2.35 1.08 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 770.06 9.87 10.73
Earnings yield (20.87%) (54.10%) (28.84%)
Free cash flow yield (11.85%) (46.74%) (23.03%)

Profitability

Metric IKT UPB Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (5,382.65%) 0.00%
Net margin 0.00% (4,955.67%) 0.00%
Free cash flow margin 0.00% (4,317.42%) 0.00%
Return on equity (51.96%) (46.05%) (57.72%)
Return on assets (48.04%) (44.61%) (49.22%)
Return on invested capital 0.00% (1,100.93%) 0.00%

Growth

Metric IKT UPB Biotechnology median
Revenue growth (TTM) 110.93% 15.98% 5.64%
EPS growth (last fiscal year) 57.76% 52.33% —
Revenue growth, 5-year CAGR (42.21%) — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric IKT UPB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 15.82 27.99 4.73
Net debt to EBITDA 3.44 2.11 0.96

Dividend

Metric IKT UPB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric IKT UPB Biotechnology median
Market cap 293.03m 283.17m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack